Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Statement re Unsolicited Approach

2 Mar 2010 07:00

RNS Number : 9142H
Cyprotex PLC
02 March 2010
 



2 March 2010

 

 

Cyprotex PLC

("Cyprotex" or the "Company")

 

 

Statement re Unsolicited Approach

In light of the recent share price movements the Board of Cyprotex (AIM: CRX) announces that it has received a highly preliminary and unsolicited approach regarding a potential offer for the Company.

It should be noted that there is no certainty that an offer will be forthcoming.

This announcement has been made without the consent of the party who made the approach.

In accordance with Rule 2.10 of The City Code on Takeovers and Mergers (the 'Code'), Cyprotex confirms that, as at the date of this announcement it had 178,957,188 ordinary shares of 0.01 pence each in issue.

 

Enquiries:

 

Cyprotex PLC

 

Anthony Baxter CEO

016 2552 5100

 

ir@cyprotex.com

www.cyprotex.com

 

 

Execution Noble & Company Limited

 

John Llewellyn-Lloyd

020 7456 9191

 

Sam Reynolds

 

 

Public Relations

 

Financial Dynamics

 

Ben Brewerton

020 7831 3113

 

Ben Atwell

 

John Dineen

 

 

 

 

Dealing Disclosure Requirements

 

Under the provisions of Rule 8.3 of the City Code on Takeovers and Mergers (the 'Code'), if any person is, or becomes, 'interested' (directly or indirectly) in 1% or more of any class of 'relevant securities' of the Company, all 'dealings' in any 'relevant securities' of the Company (including by means of an option in respect of, or a derivative referenced to, any such 'relevant securities') must be publicly disclosed by no later than 3.30pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the 'offer period' otherwise ends. If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire an 'interest' in 'relevant securities' of the Company, they will be deemed to be a single person for the purpose of Rule 8.3.

 

Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant securities' of the Company by the Company or by any of its respective 'associates', must be disclosed by no later than 12.00 noon (London time) on the London business day following the date of the relevant transaction.

 

A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, and the number of such securities in issue, can be found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

 

'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in price or securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

 

Terms in quotation marks are defined in the Code, which can be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a 'dealing' under Rule 8, you should consult the Panel.

 

If you are in any doubt as to the application of Rule 8 to you, please contact an independent financial advisor authorised under the Financial Services and Markets Act 2000, consult the Panel's website at www.thetakeoverpanel.org.uk or contact the Panel on telephone number +44 20 7638 0129; fax +44 20 7236 7013.

 

The Directors of the Company accept responsibility for the information contained in this announcement. To the best of knowledge and belief of the Directors, who have taken all reasonable care to ensure such is the case, the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

 

Execution Noble & Company Limited is acting for the Company and for no-one else in connection with the possible offer for the Company and will not regard any other person as its client nor be responsible to anyone other than the Company for providing the protections afforded to clients of Execution Noble & Company Limited nor for providing advice in relation to the possible offer or any matter referred to herein. Execution Noble & Company Limited, is authorised and regulated by the Financial Services Authority in respect of regulated activities.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OFDQLLBBBXFZBBQ
Date   Source Headline
10th Oct 20142:36 pmRNSShare Allotment CLN Final
9th Oct 20147:00 amRNSExpansion of Drug Transporter Capabilities
1st Oct 20147:00 amRNSExpansion of Toxicology Capabilities
9th Sep 20147:00 amRNSLaunch of KeratinoSensTM Service
4th Sep 20147:00 amRNSCyprotex joins CiPA initiative
29th Aug 20144:28 pmRNSListing of Loan Notes on Cayman Stock Exchange
28th Aug 20147:00 amRNSInterim Results 2014
21st Aug 20147:00 amRNSListing of Loan Notes on Cayman Stock Exchange
14th Aug 20143:30 pmRNSHolding(s) in Company
24th Jul 201412:15 pmRNSResult of AGM, GM & Further re Share Consolidation
3rd Jul 20147:00 amRNSProposed Share Consolidation & Notice of GM
1st Jul 20147:00 amRNSExpansion of Bioanalytical Capabilities
4th Jun 201411:44 amRNSDirector/PDMR Shareholding
16th Apr 201411:31 amRNSGrant of Options
25th Mar 20147:00 amRNSFinal Results
13th Mar 20144:57 pmRNSHolding(s) in Company
28th Jan 201410:46 amRNSGrant Options
28th Jan 201410:15 amRNSgrant of options
27th Jan 20144:52 pmRNSHolding(s) in Company
27th Jan 20144:19 pmRNSHolding(s) in Company
23rd Jan 20147:01 amRNSExecutive option scheme
23rd Jan 20147:00 amRNSTrading Update
2nd Jan 20147:00 amRNSAcquisition of CeeTox
19th Dec 20139:56 amRNSHolding(s) in Company
25th Nov 20139:48 amRNSDirector Dealing
5th Nov 20131:33 pmRNSReplacement: Holding(s) in Company
5th Nov 20139:44 amRNSHolding(s) in Company
5th Nov 20139:36 amRNSHolding(s) in Company
1st Oct 20131:36 pmRNSHolding(s) in Company
30th Sep 201311:43 amRNSHolding(s) in Company
26th Sep 201310:22 amRNSResult of GM & Board changes
3rd Sep 20137:00 amRNSPublication of Circular
21st Aug 20137:00 amRNSSubscription Agreement
15th Aug 20139:04 amRNSHolding(s) in Company
7th Aug 20137:00 amRNSHalf Yearly Report
24th Jul 20131:39 pmRNSDirectorate Change
18th Jul 20137:00 amRNSLaunch of new eCiphrNeuro service
17th Jul 20133:08 pmRNSResult of AGM
11th Jul 20137:00 amRNSLaunch of New Toxicity Guide
4th Jul 201310:09 amRNSHolding(s) in Company
2nd Jul 20132:09 pmRNSHolding(s) in Company
27th Jun 20134:36 pmRNSDirector/PDMR Shareholding
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
20th Jun 20137:00 amRNSTrading update
4th Jun 20137:00 amRNSIssue of Equity
21st May 20132:06 pmRNSHolding(s) in Company
21st May 20132:05 pmRNSHolding(s) in Company
1st May 20137:00 amRNSContract with U.S. EPA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.